SELLAS Q1 net loss $5.8M; cash $28.4M; reports positive OS in Phase 2 SLS009 AML trial

SELLAS Life Sciences Group, Inc.

2025-Q1 EPS reported -$0.07

Net loss of $5.8M ($0.07 per share) for Q1 2025 vs $9.6M ($0.21) in Q1 2024.
Cash and cash equivalents $28.4M as of March 31, 2025; plus $4.0M from warrant exercises in April 2025.
Phase 2 SLS009 in r/r AML: mOS 8.9 mo (AML-MRC) and 8.8 mo (venetoclax-resistant), beating historic 2.5 mo.
Phase 3 REGAL (GPS) interim analysis supports continuation; final analysis expected 2025.
Closed $25M registered direct offering in Jan 2025; net proceeds for working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.